ArticleJournal of proteome research2012
Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.
Article in Journal of proteome research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 95 citations in OpenAlex.
- Assessment of the Therapeutic Potential of Persimmon Leaf Extract on Prediabetic Subjects.Molecules and cells · 2017Trial
- Trial
- Skin melanoma cells produce diverse gelsolin (GSN) isoforms, which play non-redundant roles in cells' proliferation and motility.Cancer cell international · 2025Article
- Serum proteomics reveals survival-associated biomarkers in pancreatic cancer patients treated with chemoimmunotherapy.iScience · 2025Article
- Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma.Oncogenesis · 2025Review
- Lumican, a Multifunctional Cell Instructive Biomarker Proteoglycan Has Novel Roles as a Marker of the Hypercoagulative State of Long Covid Disease.International journal of molecular sciences · 2024Review
- Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data.EClinicalMedicine · 2023Article
- Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.International journal of molecular sciences · 2022Article
- Proteomic Profiling of Plasma-Derived Biomarkers in Patients with Bladder Cancer: A Step towards Clinical Translation.Life (Basel, Switzerland) · 2021Article
- Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.Molecules (Basel, Switzerland) · 2021Review
- Current State of "Omics" Biomarkers in Pancreatic Cancer.Journal of personalized medicine · 2021Review
- Article
- Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients.Cancers · 2020Article
- Proteome alterations in pancreatic ductal adenocarcinoma.Cancer letters · 2020Review
- A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic.Cancer science · 2019Article
- Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target.International journal of molecular sciences · 2018Review
- Article
- Tailored Use of Targeted Proteomics in Plant-Specific Applications.Frontiers in plant science · 2018Article
- Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel.Oncotarget · 2017Article
- Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis.Cancer medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Biomarkers are most frequently proteins that are measured in the blood. Their development largely relies on antibody creation to test the protein candidate performance in blood samples of diseased versus nondiseased patients. The creation of such antibody assays has been a bottleneck in biomarker progress due to the cost, extensive time, and effort required to complete the task. Targeted proteomics is an emerging technology that is playing an increasingly important role to facilitate disease biomarker development. In this study, we applied a SRM-based targeted proteomics platform to directly detect candidate biomarker proteins in plasma to evaluate their clinical utility for pancreatic cancer detection. The characterization of these protein candidates used a clinically well-characterized cohort that included plasma samples from patients with pancreatic cancer, chronic pancreatitis, and healthy age-matched controls. Three of the five candidate proteins, including gelsolin, lumican, and tissue inhibitor of metalloproteinase 1, demonstrated an AUC value greater than 0.75 in distinguishing pancreatic cancer from the controls. In addition, we provide an analysis of the reproducibility, accuracy, and robustness of the SRM-based proteomics platform. This information addresses important technical issues that could aid in the adoption of the targeted proteomics platform for practical clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.